Die Mpox verbreiten sich derzeit weltweit. Ein Forschungsteam der Goethe-Universität und der University of Kent hat nun einen Wirkstoff identifiziert, der gegen die Krankheit helfen könnte.

This year`s congress provided overall survival (OS) results from the SOLO-1/GOG 3004 and PAOLA-1/ENGOT-ov25 trials investigating olaparib (ola) alone and in combination with bevacizumab (bev) as maintenance therapy in patients with advanced ovarian cancer (AOC). Based on the results of randomized phase 3 trials, Poly(adenosine diphosphate-ribose) pol-ymerase inhibitors (PARPi) have been approved as a new standard of care in AOC and have revolutionized the way patients are treated in the front-line (1–4) and recurrent setting (5–7). Currently, ola, niraparib, ola plus bev and bev demonstrated significant improvements in progression-free survival (PFS) and are approved for first-line maintenance therapy (1, 3, 4, 8)

One of the highlights of this year’s congresses was the presentation of the results of the study by Dr. Blaye et al. on an immunological signature to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease after neoadjuvant chemo-therapy (NACT) (1) .

We selected two studies in the field of lung cancer presented at this year’s ESMO congress as highlights of the year. Both studies deal with targeted therapies in metastatic non-small cell-lung cancer (NSCLC).

Myeloproliferative Neoplasms (MPNs) are clonal hematopoietic stem cell disorders that have a proliferative nature and a variable tendency to transform into myelofibrosis and acute leukemia. In addition to symptom relief and prevention of thromboembolic as well as bleeding events, the treatment goal of disease modification has become increasingly important in recent years. We summarize two abstracts focusing on the treatment of Poly-cythemia vera (PV) and Primary Myelofibrosis (PMF).